ELDN · CIK 1404281
What Eledon Pharmaceuticals, Inc. told the SEC could break it.
Eledon's disclosures describe a pre-revenue, single-asset biotech: it has poured substantially all of its resources into one lead candidate, tegoprubart, with no approved products, a $45.6 million net loss in 2025 and a $401.2 million accumulated deficit, so its entire value rests on that one clinical-stage program. It owns no manufacturing and relies entirely on third parties for raw materials and the production, labeling, storage and distribution of tegoprubart, leaving its supply outside its control. That outsourced chain is exposed to trade policy — a proposed 100% U.S. tariff on branded and patented pharmaceuticals, plus a national-security import investigation — that could raise costs or delay supply.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- single-product (tegoprubart) dependence; pre-revenue with recurring lossesmedium
Eledon has invested substantially all resources in its lead candidate tegoprubart, has no approved products or revenue, a $45.6M 2025 net loss and a $401.2M accumulated deficit — concentrating its entire value in one clinical-stage program.
“We have invested substantially all of our efforts and financial resources in the development of our lead drug candidate tegoprubart, including funding non-clinical studies, clinical trials, drug formulation and the manufacturing of clinical trial materials.”
SEC filing →As of 2026
Regulatory & policy
- proposed 100% tariff on branded/patented pharmaceuticals; Section 232 pharma import probemedium
A proposed 100% U.S. tariff on branded/patented pharmaceutical products (and a national-security import investigation) could raise the cost of, or delay, drug substance/product Eledon obtains from its manufacturers.
“Further, the U.S. government has proposed a 100% tariff on branded and patented pharmaceutical products. All of these current and threatened tariffs are subject to implementation or change with little notice.”
Supplier concentration
- no internal manufacturing; full reliance on third-party CMOs for raw materials and drug substance/productmedium
Eledon owns no manufacturing facilities and relies entirely on third parties for raw materials and the manufacture, labeling, storage and distribution of tegoprubart drug substance/product for its clinical activities.
“We currently rely on third parties for raw materials and the manufacturing of drug substance and drug product for non-clinical and clinical activities.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch